We’re Forging New Pathways in the Fight Against Cancer.

Our diversified portfolio of clinical and pre-clinical assets presents a pioneering new approach that doesn’t sacrifice tolerability for efficacy.

Aprea’s precision oncology pioneers develop highly selective, potentially less toxic DDR-targeted therapeutics that are designed to address a significant unmet medical need for cancer patients with mutations in DNA damage response (DDR) genes.

Our diversified portfolio of clinical and pre-clinical assets presents a pioneering new approach that maximizes efficacy by improving tolerability.

See what makes us different

DDR-Targeted Solutions

Aprea’s unique approach to synthetic lethality is revolutionizing the future of cancer treatment.

Learn about our solutions

Pipeline

Aprea’s robust pipeline explores multiple targets to improve our chances of success.

Learn about our pipeline

Clinical Trials

Clinical trials put Aprea closer to bringing breakthrough DDR-targeted therapies to market.

Learn about our clinical trials

Team

Our experienced management and board of directors values the role of investors in our mission to save lives.

Learn about our team

A Groundbreaking Approach to DDR-Targeted Therapeutics